Competitive Readiness
Our competitive readiness capabilities have established Deallus as a trusted partner to many of the world’s leading life sciences companies.
Our capability-building, based on the compelling competitor and market insights we unearth, underpins client strategic decision-making, reinforces competitive mindsets and strengthens brand planning processes to enhance competitive readiness across all relevant divisions, functions and geographies.
CI manager training
Integrating competitive intelligence and the management of CI within an organisation
Training the trainer
Developing internal competitive intelligence champions to drive the value of CI throughout the organisation
Building a competitive mindset
Integrating competitive insights into meaningful brand planning
Training field teams
Sales force training centered on developing a competitive mindset and demystifying competitive challenges
The Future of JAK Inhibitors
From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.
Digitizing Healthcare
Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace. In this white paper we explore the digitization trend currently infiltrating healthcare and delve into the implications of digital health on patients, payers, and pharma itself. We take stock of the current landscape, discuss likely future trends, and explore how strategic intelligence can help answer key questions for the healthcare industry in the face of so much digital innovation.
Let’s talk about NASH
Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States. Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.